Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA (NYSE:IQV) and Kexing Biopharm (688136.SH) are expanding a strategic collaboration to support a global, multi-product biosimilar development and commercialization program. The alliance combines IQVIA’s end-to-end clinical, regulatory, analytics and commercialization capabilities with its AI-enabled clinical trial platform to streamline protocol design, site selection and study conduct for Kexing’s international expansion.
IQVIA (NYSE:IQV) said its board approved a $2.0 billion increase to its share repurchase authorization, raising the remaining Repurchase Program capacity to $3.2 billion as of May 7, 2026.
The program has no expiration date, may be suspended or modified, and repurchases may occur in open‑market, block or private transactions at management's discretion.
IQVIA (NYSE:IQV) announced that CFO Mike Fedock will speak at the Bank of America Health Care Conference in Las Vegas on May 13, 2026 at 1:40 p.m. ET. A live audio webcast and same-day replay will be available via IQVIA's Investor Relations website.
IQVIA (NYSE:IQV) reported first-quarter 2026 results: revenue of $4,151 million (+8.4% reported, +6.0% cc), GAAP net income of $274 million, adjusted EBITDA of $932 million, and adjusted diluted EPS of $2.90. R&D contracted backlog was $34.2 billion.
Operating cash flow was $618 million, free cash flow $491 million (100% of adjusted net income); repurchased $552 million of stock. Full‑year revenue and adjusted EBITDA guidance reaffirmed; adjusted diluted EPS guidance raised to $12.65–$12.95.
IQVIA (NYSE:IQV) will report first-quarter 2026 results before market open on Tuesday, May 5, 2026, and will host a conference call and webcast at 9:00 a.m. ET.
Financials, presentation slides, registration details, live webcast and replay will be available on the IQVIA Investor Relations website. Registered callers receive dial-in, passcode and registrant ID by email.
IQVIA (NYSE:IQV) on March 16, 2026 launched IQVIA.ai, a unified agentic AI platform built with NVIDIA Nemotron, NeMo Agent Toolkit, Dynamo and LangChain to accelerate clinical, commercial and real-world workflows while meeting healthcare regulatory, privacy and quality standards.
IQVIA reported a collaboration with NVIDIA of more than one year, filed over 100 AI-related patents, deployed more than 150 intelligent agents, and said 19 of the top 20 pharmaceutical companies have begun using IQVIA agents; expanded capabilities expected in Q4.
IQVIA (NYSE:IQV) announced that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026 at 9:30 a.m. ET.
A live audio webcast will be available on the company investor relations website, with a replay posted later the same day.
IQVIA (NYSE:IQV) announced that chairman and CEO Ari Bousbib will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 9:20 a.m. ET. A live audio webcast will be available on the IQVIA Investor Relations website, with a replay available later that day.
IQVIA (NYSE: IQV) published its 2025 Sustainability Report, highlighting progress across People, Public and Planet pillars. Key metrics include >230,000 AI learning engagements, >2,000 leadership program participants, activation of Brazil and Argentina sites enrolling 5,700 patients toward a 47,000 global trial target, and 56 Prime Sites.
Environmental actions include 100% My Green Lab certification, test kits using ≥98% recycled materials and a 70% cut in cold‑chain packaging emissions.
IQVIA (NYSE: IQV) announced it will acquire certain discovery services assets from Charles River Laboratories, adding five sites that offer in vitro New Approach Methodologies (NAMs) and a small-molecule AI platform.
The assets include >20 years of curated scientific data, have supported 100+ molecules entering clinical trials and several approved drugs. The deal expands IQVIA Laboratories into an end-to-end drug discovery platform. The transaction is expected to close in the second quarter, 2026.